BTA 0.00% 57.0¢ biota holdings limited

ann coming down : 2 mill grant, page-15

  1. 886 Posts.
    lightbulb Created with Sketch. 1


    http://www.sunherald.com/2011/06/10/3184498/biota-obtains-us29m-nih-grant.html#ixzz1Ov8qJCuB


    Management need to sell the full story and update the company profile "About Biota" to include the Inavir BARDA grant and progression to ROW


    "Biota is a leading anti-infective drug development company based in Melbourne Australia, with key expertise in respiratory diseases, particularly influenza. Biota developed the first-in-class neuraminidase inhibitor, zanamivir, subsequently marketed by GlaxoSmithKline as Relenza?. Biota research breakthroughs include a series of candidate drugs aimed at treatment of respiratory syncytial virus (RSV) disease and Hepatitis C (HCV) virus infections. Biota has clinical trials underway with its lead compound for human rhinovirus (HRV) infection in patients with compromised respiration or immune systems.

    In addition, Biota and Daiichi Sankyo co-own a range of second generation influenza anti-virals, of which the lead product, lnavir?, is approved for marketing in Japan.

    Relenza? is a registered trademark of the GlaxoSmithKline group of companies.

    Inavir? is registered to Daiichi Sankyo."



    Read more: http://www.sunherald.com/2011/06/10/3184498/biota-obtains-us29m-nih-grant.html#ixzz1Ov8qJCuB

 
watchlist Created with Sketch. Add BTA (ASX) to my watchlist

Currently unlisted public company.

arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.